Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Futuximab |
Synonyms | |
Therapy Description |
Futuximab (992 DS) is a recombinant human-mouse chimeric monoclonal antibody that targets a specific EGFR epitope (PMID: 29564747). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Futuximab | 992 DS|992-DS|992DS | EGFR Antibody 60 | Futuximab (992 DS) is a recombinant human-mouse chimeric monoclonal antibody that targets a specific EGFR epitope (PMID: 29564747). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03549338 | Phase II | Modotuximab Futuximab SYM004 | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | Terminated | USA | ITA | ESP | DEU | 0 |